カテゴリ： GlobalData, アメリカ, 企業調査

PTC Therapeutics Inc (PTCT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：PTC Therapeutics Inc (PTCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9790
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company’s pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mutation; an orally active small molecule to reduce the function, activity and amount of BMI1; and an investigational oral therapeutic used for the treatment of spinal muscular atrophy. PTC Therapeutics’ ataluren is in phase 3 for the treatment of nonsense mutation duchenne muscular dystrophy.The company works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

PTC Therapeutics Inc (PTCT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
Venture Financing 14
Agilis Biotherapeutics Raises US$8 Million In Venture Financing 14
Agilis Biotherapeutics Raises USD8 Million in Venture Financing 15
PTC Therapeutics Raises USD4.5 Million in Financing 16
PTC Therapeutics Raises US$60 Million In Venture Financing 17
PTC Therapeutics Raises US$2 Million In Venture Financing 19
Ptc Therapeutics Raises US$30 Million In Venture Financing 20
Partnerships 22
PTC Therapeutics Enters into Agreement with CHDI Foundation 22
Agilis Biotherapeutics and Gene Therapy Research Institution Form Joint Venture 23
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 24
Agilis Biotherapeutics Enters into Agreement with T-TOP Clinical Research 25
PTC Therapeutics Enters into Agreement with University of Pennsylvania 26
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 27
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 28
Licensing Agreements 29
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 29
Agilis Biotherapeutics Enters into Licensing Agreement with National Taiwan University 30
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 31
Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 32
Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 33
Equity Offering 34
PTC Therapeutics Raises USD124.3 Million in Public Offering of Shares 34
Agilis Biotherapeutics Raises USD12.7 Million in Private Placement of Shares 36
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 37
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 39
PTC Therapeutics Completes IPO For US$144.4 Million 41
PTC Therapeutics Raises USD53.9 Million in Private Placement of Preferred Shares 43
Debt Offering 44
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 44
Acquisition 46
PTC Therapeutics Acquires Agilis Biotherapeutics 46
Sanofi May Acquire PTC Therapeutics 47
PTC Therapeutics Inc – Key Competitors 48
PTC Therapeutics Inc – Key Employees 49
PTC Therapeutics Inc – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 52
Financial Announcements 52
Nov 05, 2018: PTC Therapeutics reports third quarter 2018 financial results and provides a corporate update 52
Aug 07, 2018: PTC Therapeutics reports second quarter 2018 financial results and provides a corporate update 54
May 09, 2018: PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update 56
Mar 06, 2018: PTC Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 58
Jan 08, 2018: PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities 60
Nov 02, 2017: PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 61
Aug 08, 2017: PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 63
May 08, 2017: PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 65
Mar 16, 2017: PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 66
Jan 09, 2017: PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna and Advance its Innovative Pipeline 68
Corporate Communications 69
Jul 24, 2017: PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development 69
Jun 05, 2017: PTC Therapeutics Announces Executive Promotions 70
Apr 10, 2017: PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs 71
Government and Public Interest 72
Feb 13, 2018: PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 72
Feb 08, 2017: PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 73
Product News 74
05/14/2018: Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting 74
05/11/2017: Agilis Biotherapeutics Announces Presentation of Five Year Follow-Up Data of Gene Therapy Treatment for AADC Deficiency 76
05/10/2017: Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency 77
04/24/2018: Agilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting 78
Product Approvals 79
Oct 31, 2017: Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia 79
Feb 09, 2017: FDA Approves EMFLAZA (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older 80
Clinical Trials 81
Oct 03, 2017: Agilis Biotherapeutics Updates on Progress in CNS Gene Therapy Programs 81
Sep 06, 2017: Agilis Biotherapeutics Updates Progress of its CNS Gene Therapy for AADC Deficiency 83
Other Significant Developments 84
Jun 25, 2018: Decode Duchenne Announces 1,000th Patient Application 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PTC Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12
Agilis Biotherapeutics Raises US$8 Million In Venture Financing 14
Agilis Biotherapeutics Raises USD8 Million in Venture Financing 15
PTC Therapeutics Raises USD4.5 Million in Financing 16
PTC Therapeutics Raises US$60 Million In Venture Financing 17
PTC Therapeutics Raises US$2 Million In Venture Financing 19
Ptc Therapeutics Raises US$30 Million In Venture Financing 20
PTC Therapeutics Enters into Agreement with CHDI Foundation 22
Agilis Biotherapeutics and Gene Therapy Research Institution Form Joint Venture 23
Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 24
Agilis Biotherapeutics Enters into Agreement with T-TOP Clinical Research 25
PTC Therapeutics Enters into Agreement with University of Pennsylvania 26
Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 27
Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 28
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 29
Agilis Biotherapeutics Enters into Licensing Agreement with National Taiwan University 30
PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 31
Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 32
Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 33
PTC Therapeutics Raises USD124.3 Million in Public Offering of Shares 34
Agilis Biotherapeutics Raises USD12.7 Million in Private Placement of Shares 36
PTC Therapeutics Raises USD125 Million in Public Offering of Shares 37
PTC Therapeutics Completes Public Offering Of Shares For US$126.5 Million 39
PTC Therapeutics Completes IPO For US$144.4 Million 41
PTC Therapeutics Raises USD53.9 Million in Private Placement of Preferred Shares 43
PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 44
PTC Therapeutics Acquires Agilis Biotherapeutics 46
Sanofi May Acquire PTC Therapeutics 47
PTC Therapeutics Inc, Key Competitors 48
PTC Therapeutics Inc, Key Employees 49
PTC Therapeutics Inc, Other Locations 50
PTC Therapeutics Inc, Subsidiaries 50

List of Figures
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[PTC Therapeutics Inc (PTCT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Viridian Energy Supply Ltd.-エネルギー分野：企業M&A・提携分析
    Summary Viridian Energy Supply Ltd. (trading as Energia) a subsidiary of Viridian Group Investments Limited, is a vertically integrated energy company that supplies electricity and gas; and provides energy efficiency services. It provides energy to micro, small and medium-sized enterprises, and resi …
  • e.l.f. Beauty, Inc. (ELF)：企業の財務・戦略的SWOT分析
    e.l.f. Beauty, Inc. (ELF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MasTec Inc (MTZ)：企業の財務・戦略的SWOT分析
    MasTec Inc (MTZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mallinckrodt LLC：医療機器：M&Aディール及び事業提携情報
    Summary Mallinckrodt LLC (Mallinckrodt), formerly Therakos Inc, a subsidiary of Mallinckrodt Plc, is a provider of autologous immune cell therapy through extracorporeal photopheresis. The company provides Therakos Cellex Photopheresis system, which is indicated for use in ultraviolet-A irradiation i …
  • Flynn Pharma Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Flynn Pharma Ltd (Flynn Pharma) is a pharmaceutical company that manufactures and markets barbiturate products, and oral and injectable antibiotics. The company’s products include cefuroxime, circadin, distaclor, keflex, medikinet tablets, medikinet XL capsules, nebcin, nizatidine, phenytoin …
  • Purdue Pharma LP：製薬・医療：M&Aディール及び事業提携情報
    Summary Purdue Pharma LP (Purdue) is a privately held, US-based pharmaceutical company which develops pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture and marketing of prescription medicines and over-the-counter (OTC) med …
  • Bank Leumi (UK) plc：企業の戦略的SWOT分析
    Bank Leumi (UK) plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Deli Management, Inc. ：企業の戦略・SWOT・財務情報
    Deli Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Deli Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hangzhou Tigermed Consulting Co Ltd (300347)：企業の財務・戦略的SWOT分析
    Summary Hangzhou Tigermed Consulting Co Ltd (Tigermed) is a contract research organization (CRO) that provides clinical trial services. It offers regulatory submission and approval, medical translation and GMP (Good Manufacturing Practice) consulting, medical monitoring, project management, medical …
  • Archrock Partners LP：企業のM&A・事業提携・投資動向
    Archrock Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Archrock Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Fluxion Biosciences Inc：医療機器：M&Aディール及び事業提携情報
    Summary Fluxion Biosciences Inc (Fluxion) is a provider of analytical instruments for functional cellular analyses. The company’s liquid biopsy technologies include IsoFlux CTC liquid biopsy system, ERASE-Seq variant caller for liquid biopsies and the Spotlight 59 for ultra-sensitive NGS mutation de …
  • Delta Apparel, Inc. (DLA)：企業の財務・戦略的SWOT分析
    Delta Apparel, Inc. (DLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EDF Renewable Energy Inc-エネルギー分野：企業M&A・提携分析
    Summary EDF Renewable Energy, Inc. (EDF Renewable Energy), formerly, enXco, Inc., is an integrated energy company. The company designs, develops, constructs and operates renewable energy projects in the biogas, biomass, hydro, solar, wind and marine energy sectors; and provides storage solutions. It …
  • AVEO Pharmaceuticals Inc (AVEO)：製薬・医療：M&Aディール及び事業提携情報
    Summary AVEO Pharmaceuticals Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candida …
  • Woodside Petroleum Limited：企業の戦略・SWOT・財務分析
    Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report Summary Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Furukawa Electric Co Ltd (FUWAY)：企業の財務・戦略的SWOT分析
    Furukawa Electric Co Ltd (FUWAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Donaldson Company, Inc.：企業の戦略・SWOT・財務分析
    Donaldson Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Donaldson Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Corindus Vascular Robotics Inc (CVRS)：企業の財務・戦略的SWOT分析
    Summary Corindus Vascular Robotics Inc (Corindus) is a medical device company that designs, manufactures and commercializes remote robotic systems for interventional surgical procedures. The company offers next-generation CorPath GRX system, a robotic platform that enables improvements in procedural …
  • Falck Renewables S.p.A. (FKR)：企業の財務・戦略的SWOT分析
    Falck Renewables S.p.A. (FKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Volta River Authority-エネルギー分野：企業M&A・提携分析
    Summary Volta River Authority (VRA) is a state-owned energy utility that generates, transmits, and distributes electricity. The authority produces power from solar, hydro, light crude oil, distillate fuel oil, and heavy fuel oil sources. It procures energy from Takoradi International Company Ltd; an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆